Proinflammatory cytokines and cytokine production pathways

Proinflammatory cytokines are a diverse group of signaling proteins, including tumor necrosis factor-alpha (TNF-α), interleukin-1 (IL-1), and interleukin-6 (IL-6), that are primarily secreted by activated macrophages and T cells to initiate and amplify the immune response [1, 2]. These molecules bind to specific cell-surface receptors, triggering intracellular signaling pathways such as the NF-κB, MAPK, and JAK-STAT cascades, which lead to the expression of genes involved in inflammation, cell recruitment, and tissue remodeling [2, 4]. While essential for host defense against pathogens, the chronic or excessive production of these cytokines is a central driver of autoimmune diseases, chronic inflammatory conditions, and life-threatening systemic events like cytokine storms [1, 5]. Therapeutic intervention typically involves the use of monoclonal antibodies to sequester cytokines or small molecules to inhibit the enzymatic components of their production and signaling pathways [3]. Although highly effective in treating conditions like rheumatoid arthritis and psoriasis, these therapies carry significant risks of systemic immunosuppression and opportunistic infections [3, 4]. (Sources: [1] StatPearls: Physiology, Cytokines; [2] International Anesthesiology Clinics: Cytokines, Inflammation, and Pain; [3] Nature Medicine: TNF as a therapeutic target; [4] Immunological Reviews: JAK and STAT signaling; [5] Frontiers in Immunology: Cytokine Release Syndrome).

Other names

Inflammatory cytokinesPro-inflammatory mediatorsCytokine signaling cascadesPro-inflammatory cytokine production

Drugs targeting these pathways function by neutralizing circulating cytokine ligands, competitively inhibiting their cell-surface receptors, or blocking intracellular signaling enzymes such as Janus kinases (JAKs) to prevent the transcription of inflammatory genes [3, 4].